6-(cyclohexylamino)-9-[2-(4-methylpiperazin-1-yl)-ethyl]-9H-purine-2-carbonitrile
Star0
Identification
- Generic Name
- 6-(cyclohexylamino)-9-[2-(4-methylpiperazin-1-yl)-ethyl]-9H-purine-2-carbonitrile
- DrugBank Accession Number
- DB07965
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
- Weight
- Average: 368.4792
Monoisotopic: 368.243692936 - Chemical Formula
- C19H28N8
- Synonyms
- 6-(Cyclohexylamino)-9-[2-(4-methyl-1-piperazinyl)ethyl]-9H-purine-2-carbonitrile
- External IDs
- NVP-ABE854
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UCathepsin K Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as 6-alkylaminopurines. These are compounds that contain an alkylamine group attached at the 6-position of a purine. Purine is a bicyclic aromatic compound made up of a pyrimidine ring fused to an imidazole ring.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Imidazopyrimidines
- Sub Class
- Purines and purine derivatives
- Direct Parent
- 6-alkylaminopurines
- Alternative Parents
- Secondary alkylarylamines / N-methylpiperazines / Aminopyrimidines and derivatives / N-substituted imidazoles / Imidolactams / Heteroaromatic compounds / Trialkylamines / Nitriles / Azacyclic compounds / Organopnictogen compounds show 1 more
- Substituents
- 1,4-diazinane / 6-alkylaminopurine / Amine / Aminopyrimidine / Aromatic heteropolycyclic compound / Azacycle / Azole / Carbonitrile / Heteroaromatic compound / Hydrocarbon derivative show 15 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- nitrile, N-alkylpiperazine, N-methylpiperazine, 6-aminopurines (CHEBI:43341)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Not Available
- CAS number
- Not Available
- InChI Key
- OGODDSLNRULSMM-UHFFFAOYSA-N
- InChI
- InChI=1S/C19H28N8/c1-25-7-9-26(10-8-25)11-12-27-14-21-17-18(22-15-5-3-2-4-6-15)23-16(13-20)24-19(17)27/h14-15H,2-12H2,1H3,(H,22,23,24)
- IUPAC Name
- 6-(cyclohexylamino)-9-[2-(4-methylpiperazin-1-yl)ethyl]-9H-purine-2-carbonitrile
- SMILES
- CN1CCN(CCN2C=NC3=C(NC4CCCCC4)N=C(N=C23)C#N)CC1
References
- General References
- Not Available
- External Links
- PubChem Compound
- 5288616
- PubChem Substance
- 99444436
- ChemSpider
- 4450743
- BindingDB
- 19746
- ChEMBL
- CHEMBL363847
- ZINC
- ZINC000022932245
- PDBe Ligand
- IHE
- PDB Entries
- 1u9v
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.494 mg/mL ALOGPS logP 2.18 ALOGPS logP 2.19 Chemaxon logS -2.9 ALOGPS pKa (Strongest Acidic) 16.5 Chemaxon pKa (Strongest Basic) 7.93 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 7 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 85.9 Å2 Chemaxon Rotatable Bond Count 5 Chemaxon Refractivity 107.46 m3·mol-1 Chemaxon Polarizability 41.33 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9947 Blood Brain Barrier + 0.9028 Caco-2 permeable - 0.5085 P-glycoprotein substrate Substrate 0.808 P-glycoprotein inhibitor I Non-inhibitor 0.6401 P-glycoprotein inhibitor II Inhibitor 0.6671 Renal organic cation transporter Inhibitor 0.7675 CYP450 2C9 substrate Non-substrate 0.7931 CYP450 2D6 substrate Non-substrate 0.5171 CYP450 3A4 substrate Substrate 0.5209 CYP450 1A2 substrate Inhibitor 0.5575 CYP450 2C9 inhibitor Non-inhibitor 0.8144 CYP450 2D6 inhibitor Non-inhibitor 0.6825 CYP450 2C19 inhibitor Non-inhibitor 0.8815 CYP450 3A4 inhibitor Non-inhibitor 0.9436 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.763 Ames test Non AMES toxic 0.6567 Carcinogenicity Non-carcinogens 0.9652 Biodegradation Not ready biodegradable 0.997 Rat acute toxicity 2.6304 LD50, mol/kg Not applicable hERG inhibition (predictor I) Strong inhibitor 0.5379 hERG inhibition (predictor II) Inhibitor 0.6998
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
1. DetailsCathepsin K
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Proteoglycan binding
- Specific Function
- Closely involved in osteoclastic bone resorption and may participate partially in the disorder of bone remodeling. Displays potent endoprotease activity against fibrinogen at acid pH. May play an i...
- Gene Name
- CTSK
- Uniprot ID
- P43235
- Uniprot Name
- Cathepsin K
- Molecular Weight
- 36965.82 Da
References
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
Drug created at September 15, 2010 21:27 / Updated at June 12, 2020 16:52